MA30781B1 - Inhibiteur de kinase - Google Patents

Inhibiteur de kinase

Info

Publication number
MA30781B1
MA30781B1 MA31765A MA31765A MA30781B1 MA 30781 B1 MA30781 B1 MA 30781B1 MA 31765 A MA31765 A MA 31765A MA 31765 A MA31765 A MA 31765A MA 30781 B1 MA30781 B1 MA 30781B1
Authority
MA
Morocco
Prior art keywords
kinase inhibitor
solvates
compound
salts
prodrugs
Prior art date
Application number
MA31765A
Other languages
English (en)
Inventor
Timothy A Gillespy
Paul Eynott
Elizabeth M Allen
Kin T Yu
Asher Zilberstein
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA30781B1 publication Critical patent/MA30781B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I), AINSI QUE LES PROMÉDICAMENTS ET LES SELS ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DE CES COMPOSÉS ET LES PROMÉDICAMENTS DE CES SELS ET SOLVATES. UN TEL COMPOSÉ POSSÈDE DES PROPRIÉTÉS PHARMACEUTIQUES AVANTAGEUSES, EN PARTICULIER LA CAPACITÉ À INHIBER DES PROTÉINES KINASES.
MA31765A 2006-09-11 2009-04-06 Inhibiteur de kinase MA30781B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82516806P 2006-09-11 2006-09-11

Publications (1)

Publication Number Publication Date
MA30781B1 true MA30781B1 (fr) 2009-10-01

Family

ID=39032357

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31765A MA30781B1 (fr) 2006-09-11 2009-04-06 Inhibiteur de kinase

Country Status (32)

Country Link
US (2) US8658649B2 (fr)
EP (1) EP2094708B1 (fr)
JP (1) JP5161237B2 (fr)
KR (1) KR101443056B1 (fr)
CN (2) CN101511838A (fr)
AR (1) AR062745A1 (fr)
AU (1) AU2007296592B8 (fr)
BR (1) BRPI0716781A2 (fr)
CA (1) CA2663175C (fr)
CL (1) CL2007002617A1 (fr)
CO (1) CO6160236A2 (fr)
CR (1) CR10636A (fr)
DK (1) DK2094708T3 (fr)
ES (1) ES2437318T3 (fr)
GT (1) GT200900055A (fr)
HN (1) HN2009000455A (fr)
IL (1) IL197381A (fr)
MA (1) MA30781B1 (fr)
MX (1) MX2009002616A (fr)
MY (1) MY148107A (fr)
NI (1) NI200900021A (fr)
NO (1) NO20091265L (fr)
NZ (1) NZ575496A (fr)
PE (1) PE20081372A1 (fr)
PT (1) PT2094708E (fr)
RU (1) RU2440352C2 (fr)
TN (2) TN2009000050A1 (fr)
TW (1) TWI399379B (fr)
UA (1) UA94622C2 (fr)
UY (1) UY30584A1 (fr)
WO (1) WO2008033798A2 (fr)
ZA (1) ZA200901073B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101261514B1 (ko) 2008-02-25 2013-05-07 에프. 호프만-라 로슈 아게 피롤로피라진 키나아제 저해제
CN101952295B (zh) 2008-02-25 2013-11-20 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
CA2716223A1 (fr) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Inhibiteurs de kinase pyrrolopyrazine
EP2247593B1 (fr) 2008-02-25 2011-08-10 F. Hoffmann-La Roche AG Inhibiteurs de kinase pyrrolopyrazine
ATE522536T1 (de) 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
CA2717991A1 (fr) * 2008-03-10 2009-09-17 Sanofi-Aventis Traitement pour des troubles oculaires
FR2929851B1 (fr) * 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
PA8851701A1 (es) 2008-12-03 2010-07-27 Sanofi Aventis Tratamiento para la glomerulonefritis
AU2009322409A1 (en) 2008-12-04 2011-06-23 Sanofi Crystalline forms
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
DK2516434T3 (en) 2009-12-23 2015-08-31 Takeda Pharmaceutical FUSED HETEROAROMATIC PYRROLIDINONS AS SICK INHIBITORS
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
RU2012152354A (ru) 2010-05-20 2014-06-27 Ф. Хоффманн-Ля Рош Аг Производные пирролопиразина в качестве ингибиторов syk и jak
BR112012029437A2 (pt) * 2010-05-20 2017-03-07 F Hoffmann - La Roche Ag derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk
EP2441755A1 (fr) 2010-09-30 2012-04-18 Almirall, S.A. Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase
WO2012177714A1 (fr) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Dérivés de 6-aza-isoindolin-1-one substitués
CA2876543A1 (fr) * 2012-08-21 2014-02-27 F. Hoffmann-La Roche Ag Pyrrolo[2,3-b]pyrazines comme inhibiteurs de syk
JP6159028B2 (ja) 2013-07-31 2017-07-05 ギリアード サイエンシーズ， インコーポレイテッド Ｓｙｋ阻害剤
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN116969927B (zh) * 2023-06-07 2024-03-19 中南民族大学 一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) * 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
WO1995033748A1 (fr) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Antagonistes du recepteur de l'endotheline
FR2732969B1 (fr) 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE69728688T2 (de) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
US6312835B1 (en) 1997-02-13 2001-11-06 Queen's University At Kingston Luminescent compounds and methods of making and using same
TR199902301T2 (xx) 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
WO1998047899A1 (fr) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Pyrrolopyridines substituees utilisees dans le traitement des maladies inflammatoires
IL133430A0 (en) 1997-08-05 2001-04-30 Pfizer Prod Inc 4-AMINOPYRROLE (3, 2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS
CA2306870A1 (fr) 1997-10-20 1999-04-29 David Michael Goldstein Inhibiteurs bicycliques d'une kinase
EP1060182B1 (fr) 1998-03-06 2012-12-19 Metabasis Therapeutics, Inc. Nouveaux promedicaments pour composes contenant du phosphore
WO1999051233A1 (fr) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
EP1070064A1 (fr) 1998-04-02 2001-01-24 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
DE69942801D1 (de) 1998-05-26 2010-11-11 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
HK1039325B (en) 1998-09-18 2006-02-24 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidines as kinase inhibitors
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
EP1990343B1 (fr) 1999-12-24 2012-04-04 Aventis Pharma Limited Azaindoles
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de) * 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
WO2001070743A1 (fr) * 2000-03-20 2001-09-27 Axys Pharmaceuticals, Inc. Inhibiteurs de la protease exempte d'amidine
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
AU2001261189A1 (en) * 2000-05-03 2001-11-12 Tularik, Inc. Pyrazole antimicrobial agents
CA2412462A1 (fr) 2000-06-14 2001-12-20 Warner-Lambert Company Heterocyles bicycliques fondus -6,5
CA2424222A1 (fr) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibiteurs de la prenyl-proteine transferase
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (fr) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthese de composes heterocycliques faisant appel a une technologie micro-onde
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
US20040082365A1 (en) * 2002-07-18 2004-04-29 Celerica Ltd Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (fr) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines utilisées comme inhibiteurs de kinases
WO2005014543A1 (fr) 2003-08-06 2005-02-17 Japan Tobacco Inc. Compose a cycle condense utilise comme inhibiteur de la polymerase du vhc
BRPI0513899A (pt) * 2004-07-27 2008-05-20 Sgx Pharmaceuticals Inc moduladores de cinase heterocìclica de anel fundido
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
FR2876582B1 (fr) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20060110462A1 (en) 2004-11-08 2006-05-25 Pavlos Papadopoulos Nanoparticulate compositions of tubulin inhibitor compounds
ZA200704888B (en) * 2004-11-22 2009-02-25 Vertex Pharma Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders

Also Published As

Publication number Publication date
CA2663175C (fr) 2012-03-13
WO2008033798A2 (fr) 2008-03-20
CN101511838A (zh) 2009-08-19
EP2094708A2 (fr) 2009-09-02
CR10636A (es) 2009-03-20
TN2009000049A1 (en) 2010-08-19
ZA200901073B (en) 2009-12-30
GT200900055A (es) 2010-07-28
EP2094708B1 (fr) 2013-10-23
BRPI0716781A2 (pt) 2014-11-18
JP2010502767A (ja) 2010-01-28
AU2007296592A1 (en) 2008-03-20
UY30584A1 (es) 2008-05-02
TN2009000050A1 (en) 2010-08-19
KR101443056B1 (ko) 2014-09-22
NI200900021A (es) 2010-01-29
US20140142110A1 (en) 2014-05-22
AU2007296592B2 (en) 2011-12-15
UA94622C2 (en) 2011-05-25
PT2094708E (pt) 2014-01-07
RU2440352C2 (ru) 2012-01-20
US20100035884A1 (en) 2010-02-11
WO2008033798A3 (fr) 2008-05-15
CA2663175A1 (fr) 2008-03-20
DK2094708T3 (da) 2014-01-27
HN2009000455A (es) 2012-02-13
IL197381A0 (en) 2009-12-24
KR20090063214A (ko) 2009-06-17
TW200829590A (en) 2008-07-16
IL197381A (en) 2013-11-28
CL2007002617A1 (es) 2008-05-16
ES2437318T3 (es) 2014-01-10
JP5161237B2 (ja) 2013-03-13
US8658649B2 (en) 2014-02-25
MY148107A (en) 2013-02-28
AR062745A1 (es) 2008-12-03
PE20081372A1 (es) 2008-11-27
CO6160236A2 (es) 2010-05-20
TWI399379B (zh) 2013-06-21
AU2007296592B8 (en) 2012-01-12
MX2009002616A (es) 2009-03-24
CN103804383A (zh) 2014-05-21
RU2009113615A (ru) 2010-10-20
NO20091265L (no) 2009-04-03
NZ575496A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
UA94622C2 (en) Kinase innhibitor
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MA30952B1 (fr) Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MX2007015863A (es) Inhibidores de esfingosina cinasa.
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
HRP20040686B1 (hr) Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
MA31655B1 (fr) Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt.
TNSN08306A1 (fr) Imidazoles substitutes et leur utilisation comme pesticides
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MX2009005604A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
UY29927A1 (es) Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
TN2010000130A1 (fr) Derives de quinazolinedione, leur preparation et leurs applications therapeutiques
MX2009005691A (es) Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
ECSP088136A (es) Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa
TW200722100A (en) A therapeutic agent for a β related disorders
WO2008079873A3 (fr) Utilisation de composés thiazolyle comme inhibiteurs de kinases
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MA54386B1 (fr) Modulateurs de trex1
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors